https://orcid.org/0000-0001-7457-2552
References
- Cowie MR , FisherM. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat. Rev. Cardiol., 17, 761–772 (2020)
- Cosentino F et al. 2019 Esc guidelines on diabetes, pre-diabetes, and cardiovascular disease developed in collaboration with the EASD. Eur. Heart J., 41, 255–323 (2020).
- Das SR et al. 2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with Type 2 diabetes and atherosclerotic cardiovascular disease. J. Am. Coll. Cardiol., 72, 3200–3223 (2018).
- McMurray JJV , SolomonSD, InzucchiSEet al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med., 381(21), 1995–2008 (2019).
- Komajda M , AnkerSD, CowieMRet al. For the QUALIFY investigators. Physicians’ adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey. Eur. J. Heart Fail., 18(5), 514–522 (2016).
- Packer M , AnkerSD, ButlerJet al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med., 383(15), 1413–1424 (2020).
- Zannad F , FerreiraJP, PocockSJet al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet, 396, 819–829 (2020).
- McEwan P , DarlingtonO, McMurrayJJVet al. Cost–effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF. Eur. J. Heart Fail.doi: https://doi.org/10.1002/ejhf.1978 (2020) ( Epub ahead of print)
- Cowie MR . DAPA-HF: does dapagliflozin provide ‘bang for your buck’ as a treatment for heart failure with reduced ejection fraction?Eur. J. Heart Fail. doi:10.1002/ejhf.1982 (2020) ( Epub ahead of print).
- Perkovic V , JardineMJ, NealBet al. Canagliflozin and renal outcomes in Type 2 diabetes and nephropathy. N. Engl. J. Med., 380(24), 2295–2306 (2019).
- Heersprink HJL , StefanssonBV, Correa-RotterRet al. For the DAPA-CKD trial committees and investigators. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med., 383, 1436–1446 (2020).